Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Market for MicroRNA Tools and Services Expected to More than Double

By BiotechDaily International staff writers
Posted on 16 Sep 2013
Due to the rapid growth in microRNA (miRNA) research, the markets for reagents and instrumentation in this field as well as for miRNA service providers are expected to more than double over the next several years.

The growth of therapeutic and diagnostic enterprises, higher research funding, and increased outsourcing to contract research organizations should present immense opportunities for the miRNA tools and services market.

Data released in the new Frost & Sullivan (Mountain View, CA, USA) report "Global Analysis of MicroRNA Tools and Services Market" revealed that the market for reagents and instrumentation earned revenues of 110.0 million USD in 2012 and estimated this to more than double to reach 247.7 USD million in 2017.

The miRNA services market, which caters to academic and research institutes, core facilities, and pharmaceutical and biotech companies, earned revenues of 35.1 million USD in 2012, and this is expected to grow to 63.3 million USD in 2017.

Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays, and functional tools, qRT PCR remains the fastest growing, while microarray is gradually being replaced by next-generation sequencing platforms.

"As miRNA research evolves globally and more efficient products are required, the space is burgeoning with technology innovations," said Divyaa Ravishankar, senior research analyst at Frost & Sullivan. "Strategic alliances for product development are taking place, resulting in novel kits for qPCR and new mimics and inhibitors that help researchers shorten their project timeline and get more funding. To sustain product value until then, market participants must continue to offer technology improvements and differentiated features, and strategically compete without making deep pricing cuts that may irreversibly damage market potential. Providing complete workflow solutions and discounts when a customer purchases products along with several different portfolios will simplify purchasing and attract new customers."

Related Links:

Frost & Sullivan



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.